Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Kymera gains Fast Track status for oral candidate KT-621 for eczema [Seeking Alpha]
Kymera Therapeutics (NASDAQ:KYMR) had its "overweight" rating reaffirmed by analysts at Stephens.
Kymera Therapeutics (NASDAQ:KYMR) was given a new $120.00 price target on by analysts at Mizuho.
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis [Yahoo! Finance]